Rationale for the use of Doramycin for the eradication of microflora associated with bacterial vaginosis

Authors: P.V. Fedorych, G.I. Mavrov, Vl.V. Podolsky


The objective: to substantiate the use of the antimicrobial drug Doramycin (spiramycin) in the treatment of bacterial vaginosis (BV), taking into account the sensitivity to it of the individual components of the polyetiological disease.

Materials and methods

Using the real-time polymerase chain reaction method, a DT-96 amplificator using the Femoflor-16 reagent kit was used to examine 71 patients with chronic inflammation of the genitourinary system, in whom microorganisms associated with BV were detected. The sensitivity of the detected microflora to Doromycin has been analyzed.

Results

The overwhelming majority of microorganisms and / or groups of microorganisms (sensitivity to part of the constituent groups) associated with BV, which can be detected using the Femoflor-16 reagent kit, has been shown to be sensitive to Doramycin.

Conclusion

Doramycin is advisable to use as a drug of choice for the comprehensive treatment of bacterial vaginosis in women, as well as anaerobic and microaerophilic dysbiosis of the urinary system of men. The main additional benefits of Doromycin are the possibility of prescribing the drug during pregnancy, as well as the possibility of simultaneous eradication of both certain causative agents of bacterial vaginosis, and Chlamydia trachomatis and Ureaplasma urealyticum, the most common causative agents of inflammation of the genitourinary system today.

Key words: Doramycin, spiramycin, bacterial vaginosis, treatment, Femoflor-16 reagent kit.

Published in the journal “Women’s Health” № 01 (137) ‘2019

ARTICLES FROM CATEGORY
Support of educational events. Participation of World Medicine in the First Congress of Optometrists of Ukraine.
Cetirizine is an effective and safe antihistamine (literature review, results of clinical researches)
All-Ukrainian Scientific and Practical Conference “Aspects of Internal Medicine in Wartime 2024"

PROVE YOU ARE A MEDICAL PROFESSIONAL

Attention: This section is intended for healthcare professionals only. If you are not a medical professional, you can return to the main page by clicking the “No” option

CARD-NOTIFICATION OF AN ADVERSE DRUG REACTION AND/OR LACK OF EFFICACY OF THE MEDICINE

INFORMATION ABOUT THE PATIENT

SUSPECTED AR/LE

Suspected AR (describe each clinical manifestation of the AR with dates and times of onset and end and outcome)/Indication of the LE

INFORMATION ABOUT SUSPECTED MEDICINES

INFORMATION ABOUT RELATED MEDICINES

(with the exception of drugs used to correct the effects of AR/LE)
(concomitant diagnoses, laboratory and instrumental studies, allergy history, pregnancy with gestational age, method of conception, pregnancy outcome (if the pregnancy ended, the date of delivery, type of delivery, etc.)

Information about the messenger

INFORMATION ABOUT THE MEDICAL/PHARMACY SPECIALIST

(if not the notifier)

MESSAGE CARD for the patient

to provide the patient and/or his/her representative with information on adverse drug reactions and/or lack of efficacy of the drug

INFORMATION ABOUT THE PATIENT

Information about the suspected medicine

Information on the prescription of the suspected medicinal product

Information about the messenger

Information about the physician, healthcare facility and place of residence of the patient who had an adverse medicine reaction and/or lack of efficacy of the medicine

розробка сайту Estetic web design